# Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer

> **NCT06614231** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 48 (estimated)

## Conditions studied

- NSCLC, Stage IIIA
- NSCLC (non-small Cell Lung Cancer)

## Interventions

- **DRUG:** Tislelizumab Combined With Chemotherapy

## Key facts

- **NCT ID:** NCT06614231
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-20
- **Primary completion:** 2028-09-08
- **Final completion:** 2028-09-08
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06614231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06614231, "Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06614231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*